Allogene Therapeutics ALLO Business Segments — Other income (expenses), net

Similar metrics at other companies

CELHReportable Segment — Other (expense) income, net

-$5.73M+57.6%

PCTYReportable Segment — Other income (expense)

$753K+31.6%

REPLReportable Segment — Other Income (Expense)

$627K+147%

PYPLReportable Segment — Other Income (Expense)

-$117M-568%

AMHReportable Segment — Other income and expense, net

$327K-86.6%

PCRXReportable Segment — Total other (expense) income, net

-$1.9M-128%

FAQ

What is Allogene Therapeutics's business segments — other income (expenses), net?

Allogene Therapeutics (ALLO) reported business segments — other income (expenses), net of $3.49M in Q1 2026.

How has Allogene Therapeutics's business segments — other income (expenses), net changed year-over-year?

Allogene Therapeutics's business segments — other income (expenses), net decreased by 36.1% year-over-year, from $5.46M to $3.49M.

What is the long-term trend for Allogene Therapeutics's business segments — other income (expenses), net?

Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — other income (expenses), net has grown at a 524.9% compound annual growth rate (CAGR), from $472K to $18.43M.

What does business segments — other income (expenses), net mean?

This metric captures non-operating financial activities, such as interest income, interest expense, and foreign exchange gains or losses. It reflects the impact of the company's treasury management and capital structure on the bottom line. A positive value indicates that non-core activities are contributing to the company's financial position.